Systemic Inflammation and Multimodal Biomarkers in Amnestic Mild Cognitive Impairment and Alzheimer's Disease

Author(s):Show less -

Magalhaes, T. N. C. ^[1] ; Weiler, M. ^[1] ; Teixeira, C. V. L. ^[1] ; Hayata, T. ^[1] ; Moraes, A. S. ^[2] ; Boldrini, V. O. ^[2] ; dos Santos, L. M. ^[2] ; de Campos, B. M. ^[1] ; de Rezende, T. J. R. ^[1] ; Joaquim, H. P. G. ^[3] ; Talib, L. L. ^[3] ; Forlenza, O. V. ^[3] ; Cendes, F. ^[1] ; Balthazar, Marcio L. F. ^[1]

Affiliation

^[1] Univ Campinas UNICAMP, Dept Neurol, Neuroimaging Lab, BR-13083970 Campinas, SP - Brazil

^[2] Univ Campinas UNICAMP, Dept Genet Evolut & Bioagents, Neuroimmunol Unit, Campinas, SP - Brazil

^[3] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo - Brazil

• Document type: Journal article
• Source: Molecular Neurobiology; v. 55, n. 7, p. 5689-5697, JUL 2018.
• Web of Science Citations: 5

Abstract

There is increasing evidence suggesting that one of the most relevant pathophysiological features of Alzheimer's disease (AD) is neuroinflammation, which plays an important role in the production and regulation of AD-related proteins (amyloid beta (A beta) and Tau) and exacerbates AD pathology. Neuroinflammation can also be induced by systemic influences (factors from outside the central nervous system). However, the role of systemic inflammation in AD pathophysiology is much less understood. Thus, our main objective in this study was to verify whether the presence of serum cytokines (IL-1 beta, IL-6, IL-10, IL-12, and TNF-alpha) affects different AD biomarkers: A beta(1-42) and Tau protein levels, hippocampal volumes (HV), and default mode network functional connectivity (DMN FC) in healthy elderly controls, amnestic mild cognitive impairment (aMCI) patients due to AD, and mild AD patients. To accomplish this, we acquired 3-T MRI, blood, and cerebrospinal fluid (CSF) samples from 42 healthy controls, 55 aMCI patients due to AD, and 33 mild AD patients. Comparing the groups, we found that the mild AD patients presented smaller HV, disrupted DMN FC, and proportionally less IL-1 beta than the controls. The aMCI patients only differed from the controls in DMN FC. In intra-group comparison, aMCI and mild AD with detectable levels of cytokines (TNF-alpha, IL-1 beta, IL-10, and IL-12) had decreased DMN FC. On the other hand, patients with detectable levels of IL-10 and IL-12 presented a more favorable AD biomarkers profile (larger HV, more CSF A beta(1-42), and less p-Tau), indicating a possible protective role of these ILs. Our findings indicate a possible relationship between systemic inflammation with DMN FC disruption, hippocampal atrophy, and CSF protein levels in the subjects with mild AD and aMCI. (AU)

• FAPESP's process: 13/07559-3 - BRAINN - The Brazilian Institute of Neuroscience and Neurotechnology
• Grantee: Fernando Cendes
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC